STAMPEDE has now recruited 500 patients! This represents a major milestone for the trial, the Trial Management Group were pleased to announce, and has been reached on schedule. The total target is around 3300 patients.
"We need centres to keep up their efforts," said Prof Nick James, STAMPEDE Chief Investigator. "We also need new centres to join up in order to ensure continued success. Together, we can answer the trial questions."
STAMPEDE is an international, collaborative, multi-centre, multi-arm multi-stage (MAMS) randomised controlled trial. The principal aim is to assess the safety and effectiveness of novel approaches to treatment for men with prostate cancer using three drugs (docetaxel, zoledronic acid and celecoxib) given in combination to patients starting long-term hormone therapy. The trial is run from MRC Clinical Trials Unit and is grant-funded by Cancer Research UK with support from Novartis, Sanofi-Aventis and Pfizer.
To register your interest as a new centre please contact a member of the STAMPEDE trial team via firstname.lastname@example.org. More information on STAMPEDE (ISRCTN78818544) can be found on the trial website www.stampedetrial.org